In some aspects, disclosed herein are compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of Staphylococcus aureus. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders.
The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
C07D 231/12 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
Provided is an integrated circuit comprising: a sensor structure; a set of weighting elements, each configured to weight an output of the sensor structure; and an output accumulation element, the output accumulation element configured to collect weighted outputs of the set of weighting elements over an accumulation time.
H04N 25/47 - Capteurs d'images avec sortie d'adresse de pixelCapteurs d'images commandés par événementSélection des pixels à lire en fonction des données d'image
H04N 25/779 - Circuits de balayage ou d'adressage de la matrice de pixels
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Described herein are methods for assessing cytotoxicity of an agent. The methods include providing a target cell that has been engineered to express intracellularly a reporter that is not expressed endogenously by the target cell, exposing the target cell to an agent capable of modulating cytotoxicity and assaying the activity of the reporter, wherein a change in reporter activity relative to a reference value is indicative of the agent being able to modulate cytotoxicity of the target cell.
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
C12Q 1/44 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase une estérase
C12Q 1/66 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une luciférase
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
6.
T-BET INDUCES TUMOR CELL APOPTOSIS AND ITS UTILITY IN CANCER THERAPY
A therapeutic composition is designed for treating cancer is provided. The therapeutic composition includes at least one viral vector engineered to deliver a nucleic acid sequence encoding the T-bet (T-box transcription factor TBX21) to cancer cells originating from epithelial cells. The nucleic acid sequence encoding T-bet is operably linked to a promoter suitable for expression in the cancer cells.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
7.
ASSURANCE-DRIVEN ARCHITECTURE FOR MULTI-MODAL SENSING IN HUMAN- CYBER-PHYSICAL SYSTEMS
Embodiments include systems and methods for managing safety in a multi-sensor environment. Aspects include receiving data from a first localization system and a second localization system to identify a last known consistent location or an inconsistent area for each of a set of objects detected in an environment, identifying one or more hazards within the environment, and determining a maximum speed for each of the set of objects. Aspect also includes evaluating whether any of the set of objects are capable of entering a hazardous area of the one or more hazards within a threshold time and based on a determination that an object of the set of objects is capable of entering the hazardous area of the one or more hazards within the threshold time, performing a safety action.
Embodiments ensure localization consistency in multi-sensor environments by processing data from multiple localization systems. Aspects include receiving a first data stream from a first localization system, which includes data structures with object identifications, locations, and timestamps. Similarly, a second data stream from a second localization system provides corresponding data. The system identifies correspondences between the object identifications from both streams. For each object, it calculates the difference between the first and second locations, classifying them as consistent or inconsistent based on a predefined threshold. Aspects also include calculating the last known consistent location for each object, ensuring accurate tracking and management within the environment.
G01S 5/02 - Localisation par coordination de plusieurs déterminations de direction ou de ligne de positionLocalisation par coordination de plusieurs déterminations de distance utilisant les ondes radioélectriques
9.
COMPOUNDS AND METHODS FOR MODULATING GPCR SIGNALING
in vitroin vitro for CB2 binding and functional antagonism, achieving an experimentally validated hit rate of 55%. Our findings demonstrate the effectiveness of reliable reactions, such as Sulfur Fluoride Exchange (SuFEx) reactions, for diversifying ultra-large chemical spaces and facilitating the discovery of new lead compounds for important biological targets.
Presented herein are systems and methods for using machine learning (ML) models to identify species-biased antimicrobial peptides (SB-AMPs) that target select microbial population. A computing system may retrieve a training dataset comprising AMP sequences and non-AMP sequences. The AMP sequences may target the select microbial populations. The computing system may generate, for each of the AMP and non-AMP sequences, a respective plurality of properties. The computing system may provide as input to a ML model, the AMP sequences, the non-AMP sequences, and the respective plurality of properties for each of the AMP sequences and non-AMP sequences. The computing system may determine, based on providing the input to the ML model, a set of rules defining values for the respective plurality of properties to discriminate between the AMP sequences and the non-AMP sequences.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The stereolithography system includes a light source configured to project an image or a light onto a substrate, a rotating mirror configured to reflect the image or the light at the substrate, an actuator coupled to a linear stage and configured to move or position the linear stage, and a controller coupled to the light source, the rotating mirror and the actuator. The controller is configured to determine a rotation speed of the rotating mirror to transition speed of the linear stage ratio that keeps the image at a fixed position, project the image or the light onto the substrate at the fixed position, and operate the actuator and the rotating mirror based on the rotation speed to transition speed ratio.
B29C 64/268 - Agencements pour irradiation par faisceaux laserAgencements pour irradiation par faisceaux d’électrons [FE]
B29C 64/129 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective caractérisés par la source d'énergie à cet effet, p. ex. par irradiation globale combinée avec un masque
B29C 64/153 - Procédés de fabrication additive n’utilisant que des matériaux solides utilisant des couches de poudre avec jonction sélective, p. ex. par frittage ou fusion laser sélectif
B29C 64/393 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
B33Y 30/00 - Appareils pour la fabrication additiveLeurs parties constitutives ou accessoires à cet effet
B33Y 50/02 - Acquisition ou traitement de données pour la fabrication additive pour la commande ou la régulation de procédés de fabrication additive
G02B 26/08 - Dispositifs ou dispositions optiques pour la commande de la lumière utilisant des éléments optiques mobiles ou déformables pour commander la direction de la lumière
2222 per mole of hydrogen we advance this system as an environmentally friendly, economically, and industrially relevant approach to balance the cost of hydrogen production and distribution.
C07C 45/00 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés
C07C 5/32 - Préparation d'hydrocarbures à partir d'hydrocarbures contenant le même nombre d'atomes de carbone par déshydrogénation avec formation d'hydrogène libre
The present disclosure provides photoresponsive compounds of Formula I. Processes for synthesis of the photoresponsive compounds, as well as methods of use of the photoresponsive compounds, are also provided.
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
Methods and systems are provided for controlling wheel-legged quadrupedal robots using pose optimization and force control according to quadratic programming (QP) are disclosed. An example robotic system leverages the whole-body motion and the wheel actuation to roll over high obstacles while keeping the wheel torques to navigate the terrain. Wheel traction and balancing is employed for the robot body. Linear rigid body dynamics with wheels are used for real-time balancing control of wheel-legged robots. Further, an effective pose optimization method is implemented for locomotion over steep ramp and stair terrains. The pose optimization solves for optimal poses to enhance stability and enforce collision-fee constraints for the rolling motion over stair terrain.
G05D 1/495 - Commande de l’attitude, c.-à-d. commande du roulis, du tangage ou des embardées pour assurer la stabilité
B62D 57/024 - Véhicules caractérisés par des moyens de propulsion ou de prise avec le sol autres que les roues ou les chenilles, seuls ou en complément aux roues ou aux chenilles avec moyens de propulsion en prise avec le sol, p. ex. par jambes mécaniques spécialement adaptés pour se déplacer sur des surfaces inclinées ou verticales
B62D 57/028 - Véhicules caractérisés par des moyens de propulsion ou de prise avec le sol autres que les roues ou les chenilles, seuls ou en complément aux roues ou aux chenilles avec moyens de propulsion en prise avec le sol, p. ex. par jambes mécaniques ayant des roues et des jambes mécaniques
G05D 1/49 - Commande de l’attitude, c.-à-d. commande du roulis, du tangage ou des embardées
A system and method for coherent detection for identification of scattered laser light in a detection region. The system may have an optical sensor that collects a raw optical signal. The optical signal may be mixed with a local oscillator signal to generate a mixed baseband signal. Various processing may be performed on the mixed baseband signal. The system may use the mixed baseband signal to detect whether or not scattered laser light is in the raw optical signal.
An implantable medical device to restore brain-controlled movement and sensation after neural injury. The device comprises a brain-computer interface capable of acquiring electrocorticogram (ECoG) signals recorded directly from the surface of the brain and uses the signals to enable direct control of paralyzed muscles, limbs or extremities while simultaneously receiving signals from external sensors and converting them into electrical stimulation patterns for the brain's sensory areas.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
Techniques are disclosed herein that encompass image pre-processing and a semi-supervised clustering for optimization and analysis of immune-enriched single-cell proteomics data generated via multiplexed imaging technologies. This is achieved through an image pre-processing pipeline, which converts image data contained in one type of file (e.g., .mcd) into another type of file (e.g., .tiff) and removes artifact signals from the image data using various algorithms to generate improved image data. Thereafter, a semi-supervised clustering pipeline analyzes the improved image data using various techniques, including implementing a supervised algorithm to identify metaclusters such as general immune phenotypes (e.g., CD4−T-cells, Macrophages, Neutrophils, etc.) as well as non-immune phenotypes while implementing an unsupervised algorithm that enables the identification of specific subclusters and a more in-depth cellular status characterization.
The Trustees of the University of Pennsylvania (USA)
University of Southern California (USA)
Inventeur(s)
Loo, Boon Thau
Chen, Haoxian
Naik, Mayur Hiru
Wu, Chenyuan
Zhao, Andrew Junyl
Raghothaman, Mukund
Abrégé
Methods, systems, and computer readable media for synthesizing network specifications using input and output examples are disclosed. An example system for synthesizing network specifications using input and output examples includes a processor and a memory. The system also includes an network specification synthesizer (NSS) implemented using the processor and the memory. The NSS is configured for: receiving input and output examples associated with a network protocol; generating, using the input and output examples and a synthesis algorithm, a logical specification defining the network protocol, wherein the logical specification includes a set of rules; and outputting the logical specification.
In an exemplary embodiment, a system is provided that includes one or more sensors and a processor. The one or more sensors are configured to obtain sensor data for a vehicle. The processor is coupled to the one or more sensors, and is configured to at least facilitate selecting, using the sensor data, a physical target that includes a physical element in proximity to the vehicle as the vehicle is travelling; generating virtual content based on the sensor data; and delivering the virtual content for one or more users of the vehicle as an overlay to the physical target.
C07F 15/00 - Composés contenant des éléments des groupes 8, 9, 10 ou 18 du tableau périodique
H10K 30/00 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire
H10K 30/20 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des jonctions organiques-organiques, p. ex. des jonctions donneur-accepteur
H10K 30/30 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des hétérojonctions de masse, p. ex. des réseaux interpénétrés de domaines de matériaux donneurs et accepteurs
A miniaturized spectroscopy system includes: a spectrometer integrated circuit including: one or more on-chip sensors configured to: generate pulses of an oscillating magnetic field, and detect pulse electron paramagnetic resonance (EPR) signals in a first mode of operation, and one or more on-chip timing circuits to control the generation of the pulses.
G01N 24/10 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance paramagnétique électronique
G01R 33/60 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance paramagnétique électronique
G01N 24/08 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance magnétique nucléaire
G01R 33/30 - Dispositions pour le traitement des échantillons, p. ex. cellules d'essai, mécanismes rotationnels
G01R 33/36 - Détails électriques, p. ex. adaptations ou couplage de la bobine au récepteur
22.
NOVEL INHIBITORS OF GUANOSINE MONOPHOSPHATE SYNTHETASE AS THERAPEUTIC AGENTS
The invention provides a series of GMPS enzyme inhibitors. The invention includes potent GMPS inhibitors that specifically and covalently bind to GMPS, exhibit broad anti-cancer activity, block the infection efficiency of viruses, and have the potentials to suppress undesired immune responses. These novel inhibitors of GMPS, and their derivatives, have tremendous potentials to be used as therapeutic agents for the treatment of cancers, viral infection and immune disorders.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07C 235/56 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07C 237/42 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons non condensé du squelette carboné ayant des atomes d'azote de groupes amino liés au squelette carboné de la partie acide, en outre acylés
A retinal ganglion cell (RGC) stimulation system for an optic nerve. The system can comprise a ground electrode, a stimulation electrode, a voltage or current source connected to both the ground electrode and the stimulation electrode and configured to stimulate the stimulation electrode with an electrical waveform having a first voltage and a first current, and a controller connected to the voltage or current source and controlling the first voltage and the first current of the electrical waveform.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
24.
TRANSCUTANEOUS ELECTRICAL SPINAL CORD NEUROMODULATOR AND USES THEREOF
Scuola lnternazionale Superiore di Studi Avanzati (SISSA) (Italie)
University of Southern California (USA)
Inventeur(s)
Gad, Parag
Edgerton, Victor Reggie
Taccola, Giuliano
Kreydin, Evgeniy I.
Abrégé
In various embodiments electrical stimulators are provided for transcutaneous and/or epidural stimulation. In certain embodiments the stimulator provides one or more channels configured to provide one or more of the following stimulation patterns: i) monophasic electrical stimulation with a DC offset; ii) monophasic electrical stimulation with charge balance; iii) delayed biphasic electrical stimulation with a DC offset; iv) delayed biphasic electrical stimulation with charge balance; v) amplitude modulated dynamic stimulation; and/or vi) frequency modulated dynamic stimulation.
A61N 1/06 - Électrodes pour traitement à haute fréquence
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
25.
DIRECT HYDROGENATION OF METAL CARBONATE AND RELATED SALTS TO METHANOL, METHANE AND METAL HYDROXIDE
A liquid phase process for direct utilization of inorganic metal carbonate and related salts under hydrogenative conditions to produce value-added fuels and feedstocks such as methanol, methane, carbon monoxide, and higher hydrocarbons. Advantageously, the reaction can use heterogeneous catalysts. The hydrogenation proceeds with high selectivity and yield for the desired product at relatively low temperatures, along with co-production of metal hydroxide. The metal hydroxide can be used to capture CO2, forming metal carbonates and bicarbonates that can be reused to produce more methanol and methane, hydrocarbons and carbon monoxide, closing the loop. Such a hydrogenation process can thus also be used in a “carbon capture and recycling” manner to produce renewable methane, methanol, carbon monoxide, hydrocarbons, and other carbon feedstocks from CO2 sourced from any natural and anthropogenic emissions as well as from ambient air.
C07C 29/132 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par réduction d'un groupe fonctionnel contenant de l'oxygène
C07C 1/12 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir d'oxydes de carbone à partir d'anhydride carbonique avec de l'hydrogène
A deep neural network-based reconstruction system for accelerated magnetic resonance imaging of vessel walls. The system can comprise a magnetic resonance imaging (MRI) scanner configured to obtain an image of the vessel walls, and a computer having a processor. The processor comprises a first and second subnetwork implemented in a cascade fashion. The first subnetwork comprises a convolutional neural network (CNN) and an output correcting module. The first subnetwork receives the image and transforms the image to a reduced artifact image. The second subnetwork is an identical duplicate of the first network. The second subnetwork boosts an accuracy of the reduced artifact image to generate a visual representation of the vessel walls. A computer display terminal is connected to the processor and is configured to display the visual representation of the vessel walls.
Uses of novel peptide analogs of a θ-defensin that have been developed which provide a biphasic effect in treating infection and/or sepsis are described. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effect, and function by initially recruiting effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response characteristic of sepsis and septic shock. These novel θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensin.
Described herein are bifunctional peptides, compositions comprising A the same, and methods useful for treatment of dental caries that have been treated with silver diamine fluoride. Treatment with bifunctional peptides remineralizes the carious region to address undesirable tooth discoloration associated with silver diamine fluoride treatment.
An implantable device configured to be used within a human body that includes a plurality of electrodes positioned between at least one encapsulation layer and an outer film layer. The outer film layer is configured to flex or stretch and including a biocompatible material.
A biological structure identification system includes an optical imaging system configured to illuminate a liquid biopsy sample for a subject. The liquid biopsy sample has one or more biological structures that are labeled with one or more fluorophores associated with a fluorescence assay for a cancer allowing detection of emitted electromagnetic radiation from the liquid biopsy sample as image data. The system also includes a processing system configured to identify a cancer stage for the subject by determining a predetermined cancer stage profile from a set of predetermined cancer stage profiles to which the subject profile is most similar.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
31.
COMPOSITIONS AND METHODS FOR TREATMENT OF FUNGAL INFECTIONS
Novel peptide analogs of a θ-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These novel θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensins.
A system and method operates for diagnosis of mild traumatic brain injury (mTBI) to prevent sequelae and improve neurocognitive outcomes. The system may have a processor that receives, from a magnetic resonance imaging machine, data corresponding to magnetic resonance imaging images. By using a machine learning classifier of the processor, such as a Bayesian machine learning classifier, the processor identifies mild traumatic brain injury in a person through cortico-cortical connectome mapping from magnetic resonance imaging. The processor can also generate a human readable screen display indicative of the identified mild traumatic brain injury.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
UNIVERSITY OF MAINE SYSTEM BOARD OF TRUSTEES (USA)
Inventeur(s)
Eoh, Hyungjin
Swarts, Benjamin
Woodruff, Peter
Lee, Jae Jin
Abrégé
Disclosed herein are azidodeoxy- and aminodeoxy trehalose (TreAz and TreNH2) compounds that inhibit Mycobacterium tuberculosis (an etiological agent of TB) biofilm (an in vitro model of intent TB infection) formation via blocking of the adaptive strategy used by M. tuberculosis form biofilm, termed trehalose catalytic shift. Prior to our work, such compounds were never tested for inhibition of mycobacterial biofilm formation. Our work defined this class of compounds' mechanism of action and showed for the first time that they sensitize drug-tolerant mycobacteria to existing clinically used antibiotics. The disclosed compounds are potential drugs for adjunctive treatment of TB and related mycobacterial diseases.
A61K 31/606 - Acide salicyliqueSes dérivés ayant des groupes amino
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
34.
LIQUID BIOPSY SYSTEMS AND METHODS FOR DETERMINATION OF CANCER STAGES
This disclosure relates to a liquid biopsy system. This disclosure also relates to a liquid biopsy system and method that can be used in determination of a disease stage of a subject. This disclosure also relates to a method that uses the liquid biopsy system to propose a treatment strategy for the subject. The liquid biopsy system may be configured to obtain an image of a liquid sample belonging to the subject; extract at least one feature from each event; assign a cluster identification information for each event using a feature(s) of each event; organize all events based on the event's cluster identification information; select evenly spaced events; and generate an event collage of the subject.
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
An optical circuit includes a resonator including a nonlinear optical material having intensity-dependent absorption, an input, and an output. The optical circuit includes an optical input path coupled to the input of the resonator and provides an optical logic input, an optical reference path coherently coupled to the resonator and configured to provide a first reference signal coupled to the optical input path and a second reference signal, and an optical output path coupled to the output of the resonator and configured to receive the second reference signal. The resonator receives a combined version of the optical logic input and the first reference signal, and provides an optical output signal based on the optical logic input, the first reference signal, and an intensity threshold of the nonlinear optical material. The optical output path provides an optical logic output corresponding to an output logic state based on the optical output signal and the second reference signal. The coherent coupling of the optical reference path to the resonator is configured to provide optical gain.
H03K 19/14 - Circuits logiques, c.-à-d. ayant au moins deux entrées agissant sur une sortieCircuits d'inversion utilisant des éléments spécifiés utilisant des dispositifs opto-électroniques, c.-à-d. des dispositifs émetteurs de lumière et des dispositifs photo-électriques couplés électriquement ou optiquement
G02B 6/293 - Moyens de couplage optique ayant des bus de données, c.-à-d. plusieurs guides d'ondes interconnectés et assurant un système bidirectionnel par nature en mélangeant et divisant les signaux avec des moyens de sélection de la longueur d'onde
A Light Detection and Ranging (LIDAR) system includes a transmitter configured to transmit a frequency modulated continuous wave (FMCW) signal to an environment of the LIDAR system, a receiver configured to receive, from a target in the environment, a return signal in response to transmitting the FMCW signal, a focal plane array (FPA) coupled to at least one of the transmitter and the receiver, the FPA including a two-dimensional array of pixels, and a circuit included in the FPA and configured to control each of the two-dimensional array of pixels to at least one of: (i) transmit the FMCW signal to the environment through the two-dimensional array of pixels and (ii) receive the return signal through the two-dimensional array of pixels.
An endovascular branch coupler stent graft includes a tubular stent assembly defining a central opening and four branch channels disposed in the central opening and attached to the tubular stent assembly. The four branch channel extends along the length of tubular stent assembly. Each branch channel is configured to receive a covered stent for catheterizing a branch vessel. Similarly, the central opening configured to receive a primary stent graft for reinforcing weakened sections of a subject's aorta.
Tai Chong Cheang Steamship Co. (H.K.) Limited (Chine)
Inventeur(s)
Cronin, Stephen B.
Subramanian, Sriram
Huiskamp, Tom
Nystrom, Alec
Schroeder, William
Abrégé
A system for exhaust gas remediation includes an engine, a plasma reactor, and a pulse source. The engine emits exhaust gas that includes NO molecules and NOx molecules. The plasma reactor includes an internal chamber that is fluidly connected to the engine such that the exhaust gas flows into the internal chamber. An electrode is disposed within the internal chamber of the plasma reactor. The electrode is electrically coupled to an electrical pulse source. The electrical pulse source delivers electrical pulse to the electrode to form a plasma from the exhaust gas, which removes at least a portion of the NO molecules and at least a portion of the NOx molecules.
B01D 53/32 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par effets électriques autres que ceux prévus au groupe
B01D 53/92 - Épuration chimique ou biologique des gaz résiduaires des gaz d'échappement des moteurs à combustion
F01N 3/08 - Silencieux ou dispositifs d'échappement comportant des moyens pour purifier, rendre inoffensifs ou traiter les gaz d'échappement pour rendre les gaz d'échappement inoffensifs
39.
SYSTEM AND METHOD FOR EXTENDED AND/OR CONTINUOUS ULTRASOUND ELASTOGRAPHY
A method for manufacturing a wearable ultrasound probe is provided. The method includes forming a plurality of slits in a layer of piezoelectric material. Each slit has a kerf size less than 40 μm and a center-to-center separation between 150 μm and 250 μm. The slits define edges of a plurality of ultrasound transducer elements that are formed in the piezoelectric material. The ultrasound transducer elements are configured to produce an acoustic radiation force impulse (ARFI) in a tissue. The method further includes adhering the layer of piezoelectric material to a matching layer and implanting a bio-adhesive layer onto the matching layer. The bio-adhesive layer is configured to adhere to skin of a subject.
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Surgical implants comprising living tissue; Implants comprising living tissue; Implantable scaffolds comprising living tissue for maintaining tissue contour; Implantable scaffolds comprising living tissue for enhancing therapy
A universal optical digital logic circuit is disclosed. The universal optical digital logic circuit includes an optical waveguide configured to receive a continuous wave optical signal and emit an output signal, an optical combiner configured to receive first and second optical signals and combine the first and second optical signals to produce a combined optical signal, a photodetector configured to receive the combined optical signal and convert the output optical signal into an electrical voltage signal, and a resonator coupled to the optical waveguide and configured to receive the continuous wave optical signal and/or the electrical voltage signal. The optical waveguide is configured to emit the output signal based on the electrical voltage signal applied on the resonator.
G02B 6/43 - Dispositions comprenant une série d'éléments opto-électroniques et d'interconnexions optiques associées
G02F 1/225 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence dans une structure de guide d'ondes optique
H03K 19/14 - Circuits logiques, c.-à-d. ayant au moins deux entrées agissant sur une sortieCircuits d'inversion utilisant des éléments spécifiés utilisant des dispositifs opto-électroniques, c.-à-d. des dispositifs émetteurs de lumière et des dispositifs photo-électriques couplés électriquement ou optiquement
H03K 19/21 - Circuits OU EXCLUSIF, c.-à-d. donnant un signal de sortie si un signal n'existe qu'à une seule entréeCircuits à COÏNCIDENCES, c.-à-d. ne donnant un signal de sortie que si tous les signaux d'entrée sont identiques
43.
BIDIRECTIONAL BACKPROPAGATION AUTOENCODING NETWORKS FOR IMAGE COMPRESSION AND DENOISING
A bidirectional autoencoder learns or approximates an identity mapping as it trains a single network with a version of the new bidirectional backpropagation algorithm. Ordinary unidirectional autoencoders find many uses in image processing and in large language models. But they use separate networks for encoding and decoding. Bidirectional autoencoders use the same synaptic weights for encoding and decoding. The forward pass encodes while the backward pass decodes. Bidirectional autoencoders improved network performance and significantly reduced memory usage and used fewer parameters. Simulations compared unidirectional with bidirectional autoencoders for image compression and denoising. The models trained on the MNIST handwritten-digit and CIFAR-10 image datasets. The performance measures were the peak signal-to-noise ratio and the index of structural similarity. Bidirectional autoencoders outperformed unidirectional autoencoders and still reduced the number of trainable synaptic parameters by about 50%.
H04N 19/42 - Procédés ou dispositions pour le codage, le décodage, la compression ou la décompression de signaux vidéo numériques caractérisés par les détails de mise en œuvre ou le matériel spécialement adapté à la compression ou à la décompression vidéo, p. ex. la mise en œuvre de logiciels spécialisés
G06T 5/60 - Amélioration ou restauration d'image utilisant l’apprentissage automatique, p. ex. les réseaux neuronaux
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/63 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A system can comprise a processor and a non-transitory computer-readable storage devices storing computing instructions configured to run on the processor and cause the processor to perform receiving a magnetic resonance imaging (MRI) scan, feeding the MRI scan into a predictive algorithm, and outputting an improved MRI scan from the predictive algorithm.
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
G06T 5/60 - Amélioration ou restauration d'image utilisant l’apprentissage automatique, p. ex. les réseaux neuronaux
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
46.
TRIPLE VACCINE PROTECTS AGAINST BACTERIAL AND FUNGAL PATHOGENS VIA TRAINED IMMUNITY
An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
Provided are circuits for integrating image processing into image sensors. Multiple configurations of sensors are described that generate specific motion and shape-based responses to changes in received light intensity. These sensor configurations may be used to pre-process images and to provide additional context to light intensity data. The sensor configurations may include memory circuits and signal conditioning.
H04N 25/47 - Capteurs d'images avec sortie d'adresse de pixelCapteurs d'images commandés par événementSélection des pixels à lire en fonction des données d'image
H04N 23/71 - Circuits d'évaluation de la variation de luminosité
H04N 25/76 - Capteurs adressés, p. ex. capteurs MOS ou CMOS
H04N 25/79 - Agencements de circuits répartis entre des substrats, des puces ou des cartes de circuits différents ou multiples, p. ex. des capteurs d'images empilés
A retinal ganglion cell (RGC) stimulation system for an optic nerve. The system can comprise a ground electrode, a stimulation electrode, a voltage or current source connected to both the ground electrode and the stimulation electrode and configured to stimulate the stimulation electrode with an electrical waveform having a first voltage and a first current, and a controller connected to the voltage or current source and controlling the first voltage and the first current of the electrical waveform.
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
49.
DIETARY COMPOSITIONS TO EXTEND LONGEVITY WHILE MAXIMIZING STRENGTH AND FUNCTION
ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS (Italie)
Inventeur(s)
Longo, Valter D.
Fanti, Maura
Di Tano, Maira
Salvadori, Giulia
Abrégé
A longevity diet composition includes non-refined complex carbohydrates in an amount from about 45 to 65 percent of the total calories of the longevity diet composition, proteins in an amount from about 7 to 18 percent of the total calories of the total calories of the longevity diet composition, and healthy fats in an amount from about 20 to 40 percent of the total calories of the total calories of the longevity diet composition.
A method for developing a path plan for rollout compaction of a composite ply during composite manufacturing includes receiving ply parametric data based on characteristics of a ceramic matrix composite ply for placement on a layup tool and subsequent compaction using a compaction roller during the composite manufacturing and generating the path plan for automated manipulation of the compaction roller to compact the ceramic matrix composite ply on the layup tool based at least in part on the ply parametric data. A path planning development environment associated with the method includes at least one computing device with a processor and associated memory, a network interface, an application program storage device and a data storage device. Various examples of the method and the path planning development environment are disclosed.
B28B 23/02 - Aménagements spécialement adaptés à la fabrication d'objets façonnés avec des éléments complètement ou partiellement enrobés dans le matériau de moulage dans lesquels les éléments enrobés sont des renforcements
B28B 17/00 - Parties constitutives ou accessoires de l'appareillage à façonner le matériauMesures auxiliaires prises en liaison avec un tel façonnage
C04B 35/80 - Fibres, filaments, "whiskers", paillettes ou analogues
G06F 30/17 - Conception mécanique paramétrique ou variationnelle
51.
METHODS FOR DEVELOPING PATH PLANS FOR ROLLOUT COMPACTION OF COMPOSITE PLIES DURING COMPOSITE MANUFACTURING
Methods for developing a path plan for rollout compaction of a composite ply during composite manufacturing include: selecting a working path plan data file from a working path plan repository, running a path adaptation application program to access compaction history data files in a compaction history repository relating to the working path plan data file and to identify an inconsistency in the compaction history data files that is not resolved in the working path plan data file and generating a path adaptation for the working path plan data file based on the inconsistency that is not resolved to form an adapted path plan data file defining an adapted path plan that includes the path adaptation. Additional methods include using path plans for compaction on the layup tool, capturing image data and processing the image data to build and/or add to the compaction history data file.
B28B 17/00 - Parties constitutives ou accessoires de l'appareillage à façonner le matériauMesures auxiliaires prises en liaison avec un tel façonnage
B28B 23/02 - Aménagements spécialement adaptés à la fabrication d'objets façonnés avec des éléments complètement ou partiellement enrobés dans le matériau de moulage dans lesquels les éléments enrobés sont des renforcements
G06F 30/17 - Conception mécanique paramétrique ou variationnelle
A method for operation of a layup cell during composite manufacturing includes running a compaction application program at a robot control system of the layup cell using a path plan data file defining a path plan for automated manipulation of a compaction roller for compacting a ceramic matrix composite ply on a layup tool, capturing image data of the ceramic matrix composite ply after compaction on the layup tool using a surface imaging device, at least temporarily storing the image data for the ceramic matrix composite ply after compaction in a ply image data file and processing the ply image data file to identify one or more areas of the ceramic matrix composite ply that require re-compaction. The layup cell includes the layup tool, the ceramic matrix composite ply, the robot control system, a robotic arm and at least one end effector.
B29C 70/38 - Empilage automatisé, p. ex. utilisant des robots, par application de filaments selon des modèles prédéterminés
B29C 70/50 - Façonnage ou imprégnation par compression pour la fabrication d'objets de longueur indéfinie, p. ex. de "prepregs", de préimprégnés [SMC] ou de nappes multiaxiales [XMC]
53.
SCALABLE PHOTONIC SRAM-BASED IN-MEMORY COMPUTING AND TENSOR CORE
Provided is memory circuit comprising a plurality of ring resonators optically coupled to one or more waveguides and electrically coupled to one or more diodes, where the diodes are optically coupled to the one or more waveguides, which is configured to provide optical SRAM or another type of memory with in-memory computing. Further provided is an array of said memory circuits.
G02B 6/42 - Couplage de guides de lumière avec des éléments opto-électroniques
G02B 6/293 - Moyens de couplage optique ayant des bus de données, c.-à-d. plusieurs guides d'ondes interconnectés et assurant un système bidirectionnel par nature en mélangeant et divisant les signaux avec des moyens de sélection de la longueur d'onde
54.
METHODS FOR DERIVATION AND PROPAGATION OF AVIAN PLURIPOTENT STEM CELLS AND APPLICATIONS THEREOF
Disclosed herein are methods of deriving, producing, maintaining, or expanding embryonic stem cells (ESCs) from avian species and a culture medium used for such methods. According to various embodiments, the method includes culturing an embryo extracted from an avian egg in a culture medium to harvest cells from yolk of the avian egg; dissociating cells from the cultured embryo; isolating a morphologically undifferentiated ESC colony from the dissociated cells in a culture medium; and culturing the isolated ESC colony in the presence of ovotransferrin, thereby deriving ESCs. According to various embodiments, the culture medium includes a Wnt inhibitor; a protein kinase C (PKC) inhibitor; ovotransferrin; an inhibitor of activin receptor-like kinases-4, -5, and -7; and a leukemia inhibitory factor (LIF).
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 15/873 - Techniques de production de nouveaux embryons, p. ex. transfert nucléaire, manipulation de cellules totipotentes ou production d'embryons chimériques
55.
DISPLAY OF 3D ILLUMINATIONS USING FLYING LIGHT SPECKS
Present implementations can display 3D illuminations using Flying Light Specks (FLS). Each FLS can include a miniature (hundreds of micrometers) sized drone with one or more light sources to generate colors and textures with adjustable brightness. The FLS can be network enabled with a processor and local storage. Synchronized swarms of cooperating FLSs can render static and motion illumination of virtual objects in a pre-specified 3D volume, an FLS display. Present implementations can consider the limited flight time of an FLS on a fully charged battery and the duration of time to charge the FLS battery. Present implementations can accommodate failure of FLS as a norm of operation, rather than an exception. A hardware and software architectures for an FLS-display can compute flight paths of FLSs for illumination. With motion illuminations, one technique can minimize overall distance traveled by the FLSs significantly.
G05D 1/695 - Commande coordonnée de la position ou du cap de plusieurs véhicules pour maintenir la position des véhicules les uns par rapport aux autres, p. ex. pour les voyages en convoi ou les vols en formation
G05D 1/644 - Optimisation des paramètres de parcours, p. ex. consommation d’énergie, réduction du temps de parcours ou de la distance
G05D 1/646 - Suivi d’une trajectoire prédéfinie, p. ex. d’une ligne marquée sur le sol ou d’une trajectoire de vol
G05D 1/80 - Dispositions visant à réagir aux défaillances du système ou d’origine humaine ou à les prévenir
G05D 105/65 - Applications spécifiques des véhicules commandés pour des spectacles ou des performances
G05D 107/00 - Environnements spécifiques des véhicules commandés
An electrical circuit for clock generation includes a digital-to-time converter error scrambler configured to randomize error in a digital-to-time converter (DTC) and configured to suppress spurs of the electrical circuit, a background error compensator configured to mitigate a timing mismatch between an injection of a reference signal into the DTC at a first point and an injection of the reference signal into the DTC as a second point, and a background delay equalizer configured to calibrate errors of the electrical circuit.
A method including unsupervised feature extraction is performed to determine feature maps of a various resolutions representing a three-dimensional image of a body structure. Voxel-wise classification is performed to determine if a voxel depicts a portion of a body structure, a specific subregion or zone of the body structure, and/or a diseased portion of the body structure. The method provides similar or improved performance to benchmark methods at a reduced computational and memory burden. Classifications may be validated by a second stage classifier that uses additional features.
G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
G06V 10/70 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique
58.
CROSS-SESSION ALIGNMENT OF NEURAL RECORDINGS USING SENSORY TASKS
A new paradigm of methods and systems can enable cross-session normalization of neural recordings using sensory tasks. In this paradigm, in addition to the primary task being studied, each neural recording session also includes short sensory tasks that evoke event-related potentials (ERPs) from the low-level sensory processing of the brain. Since low-level sensory processing in the brain is expected to undergo minimal plasticity, changes in low-level sensory ERPs can be largely attributed to changes in the recording setup. The new paradigm involves collection of data from sensory task in each recording session and using that collected data to align the neural recordings of different sessions with each other. The aligned neural recordings can then be used within the system, for example in a brain-computer interface system to track mental states or to track the response to interventions such as pharmacological or neurostimulation interventions over time in a given individual.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
59.
DEEP HIERARCHICAL VARIATION AUTOENCODER FOR THE STRUCTURE-BASED DESIGN OF DRUG-LIKE MOLECULES
Provided for herein are computer implemented methods and a corresponding system comprising a generative model with a hierarchical variational autoencoder (HVAE) architecture for generating a plurality of new molecular structures based on the model being trained with one or more sources of training data. In several embodiments, the output molecules have improved characteristics of choice, such as enhanced binding affinity for a target receptor.
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p. ex. relations structurelles ou fonctionnelles ou alignement de structures
In some implementations, the system may include one or more processors. In addition, the system may include a non-transitory computer-readable storage medium containing instructions that, when executed by the one or more processors, are configured to cause the system to: store a plurality of data embeddings characterizing and corresponding to an external knowledge base; receive first input data, the first input data characterizing a first patient; receive one or more medical images associated with the first patient and a corresponding prompt requesting a classification of disease characteristics present within the one or more medical images; identify first portions of the knowledge base based on the first input data; and generate, based on at least the first portions of the knowledge base, the one or more medical images, and the corresponding prompt, the classification of disease characteristics and one or more suggested treatment modalities based on the classification of disease characteristics.
A system for nonlinear flexible inference of latent factors and/or nonlinear flexible decoding of behavior from brain signals can include one or more processors configured to: receive a plurality of brain signals; and perform flexible inference of latent factors and/or flexible decoding of behavior from the plurality of brain signals via a neural network. A brain-computer interface can include the system for nonlinear flexible inference of latent factors and/or nonlinear flexible decoding of behavior from brain signals.
An imaging structure identification system includes an optical imaging system configured to illuminate a liquid biopsy sample for a subject. The liquid biopsy sample has one or more biological structures that are labeled with one or more fluorophores associated with a fluorescence assay for a disease state allowing detection of emitted electromagnetic radiation from the liquid biopsy sample as image data. The system also includes a processing system configured to identifying the subject as being at reduced risk for having the disease state if the subject profile is similar to the first predetermined profile for subjects not being in the disease state. However, if the subject profile is not similar to the first predetermined profile for subjects not being in the disease state it is not determinative if the subject is in the disease state.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G01N 33/537 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec séparation du complexe immunologique de l'antigène ou de l'anticorps non liés
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
Techniques for determining stroke risk are provided. In some embodiments, the techniques may involve causing, using one or more light sources disposed on a headset worn by a user, light to be emitted into the head of the user. The techniques may involve obtaining, using one or more light detectors disposed on the headset, information indicative of light reflected from one more structures within the head, wherein a portion of the obtained information spans a time period during which the user was holding their breath. The techniques may involve based on the obtained information, determining one or more cerebral blood metrics. The techniques may involve providing a representation of the one or more cerebral blood metrics as input to a trained machine learning model, and determining a likelihood the user will experience a stroke over a predetermined future time period based on an output of the trained machine learning model.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
64.
SELECTIVE DECHLORINATION OF POLY(VINYL CHLORIDE) TO FORM TUNABLE BRANCHED POLYETHYLENE OR POLYETHYLENE-POLY(VINYL CHLORIDE) BLOCK COPOLYMERS
A method for dechlorinating a starting chlorinated polymer includes a step of contacting the starting chlorinated polymer with a solution that includes a cation initiator, an organosilane, and chlorinated solvent at a predetermined temperature for a sufficient time to at least partially dechlorinate the starting chlorinated polymer. Complete or partial dechlorination can be achieved depending on the reaction conditions. A block copolymer formed by the method is also provided.
C08F 8/26 - Élimination, dans la molécule, des atomes d'halogènes ou des groupes contenant des halogènes
C08F 299/00 - Composés macromoléculaires obtenus par des interréactions de polymères impliquant uniquement des réactions entre des liaisons non saturées carbone-carbone, en l'absence de monomères non macromoléculaires
65.
METHODS TO ACCELERATE STEM CELL DIFFERENTIATION TO CARDIOMYOCYTES
The disclosure provides methods of promoting stem cell differentiation into mesoderm and endoderm cell lineages comprising, for example, contacting a stem cell with an agent that reduces or eliminates gene activity of one or more endogenous small nuclear ribonucleic acid (snoRNA) molecules, wherein the snoRNA molecules comprise SNORD97 and/or SNORD133. Also provided are isolated cardiomyocytes and compositions of the same, wherein the cardiomyocytes are produced using a method described herein.
An accommodating intraocular lens (IOL) is formed from an anterior or posterior half molded as a chambered, polymer sack with a mouth opening smaller than its largest width that is mated to another half molded as a pliable bowl having a rim larger than the rest of the half. The resulting shell has a seam that is parallel to and does not cross or touch the equator such that the IOL is asymmetric between its front and back. A circular depression around the optical axis can be made in the anterior and/or posterior half such that a surrounding capsular bag seals against the rim of the depression, and an interior of the depression(s) does not touch the capsular bag.
Multi-responsive promoters are provided to enhance expression of target genes, preferably chimeric antigen receptors, so as to improve thermo-responsive inducibility as well as durability or replenishment of the chimeric antigen receptors. Highly heat-sensitive promoters are also provided, evolved through a sort-seq platform, which may be integrated with responsive elements related to CAR signaling pathways to form a positive feedback loop that allows for long-lasting CAR expression upon remote stimulation by focused ultrasound (FUS) in tumor environment. Methods of using and preparing regarding the same are also provided.
An intraocular lens (IOL) has a small, central lens suspended within a pliable housing and, when the housing is filled with liquid, is coaxially aligned with a second small lens embedded in the wall of the housing. The suspension is on a dome- or other-shaped webbing attached to an inner circumference of the wall. When filled with liquid, forces squeezing or pulling the equator of the housing, as with ciliary muscles in the eye, adjust a distance between the lenses in order to adjust focus. Optional haptics may project from points on or above and below the equator. A recess in the posterior hemisphere of the housing can keep cell growth away from an optical axis of the lens system. A third small lens can be embedded in an opposite wall of the housing and coaxially aligned with the other lenses to form a three-lens, ultra-zoom system.
An accommodating intraocular lens (IOL) is formed from an anterior or posterior half molded as a chambered, polymer sack with a mouth opening smaller than its largest width that is mated to another half molded as a pliable bowl having a rim larger than the rest of the half. The resulting shell has a seam that is parallel to and does not cross or touch the equator such that the IOL is asymmetric between its front and back. A circular depression around the optical axis can be made in the anterior and/or posterior half such that a surrounding capsular bag seals against the rim of the depression, and an interior of the depression(s) does not touch the capsular bag.
Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
An intraocular lens (IOL) has a small, central lens suspended within a pliable housing and, when the housing is filled with liquid, is coaxially aligned with a second small lens embedded in the wall of the housing. The suspension is on a dome- or other-shaped webbing attached to an inner circumference of the wall. When filled with liquid, forces squeezing or pulling the equator of the housing, as with ciliary muscles in the eye, adjust a distance between the lenses in order to adjust focus. Optional haptics may project from points on or above and below the equator. A recess in the posterior hemisphere of the housing can keep cell growth away from an optical axis of the lens system. A third small lens can be embedded in an opposite wall of the housing and coaxially aligned with the other lenses to form a three-lens, ultra-zoom system.
Described are organic photovoltaic devices comprising an anode; a cathode; and a photoactive organic material in a layer disposed between the anode and the cathode, the energy difference between the triplet energy state (T1) and the singlet energy state (S1) (ΔEST) in the photoactive organic material is less than about 300 meV; and when the organic photovoltaic device is illuminated with light having an AM1.5 spectrum, the organic photovoltaic device has an open circuit voltage of greater than 0.9 V, a power conversion efficiency of greater than 22%, and an EL external quantum efficiency >5%.
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
H10K 30/20 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des jonctions organiques-organiques, p. ex. des jonctions donneur-accepteur
H10K 30/57 - Dispositifs photovoltaïques [PV] comprenant des jonctions multiples, p. ex. des cellules PV en tandem
H10K 85/60 - Composés organiques à faible poids moléculaire
The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.
A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A target and timed-release platform having formula (1): or a pharmaceutically acceptable salt thereof; wherein: BP is a bisphosphonate group for bone targeting and retention; LK is a cleavable linking group; and Dr is a drug cargo, wherein the drug cargo is released upon cleavage of the cleavable linking group.
In alternative embodiments, provided are methods that are reliable and scalable for making disulfide bond rich peptides and proteins. In alternative embodiments, provided are oxidation refolding methods to produce disulfide bond rich peptides and proteins. In alternative embodiments, methods as provided herein can be used to make any disulfide bond-containing proteins, including but not limited to: three finger neurotoxin peptides (such as for example, rec-α-Bungarotoxin (rec-αBtx), rec-α-Cobratoxin (rec-αCTX), κ-Bungarotoxin (rec-κBtx), rec-MTa, rec-hannalgesin, rec-Mambalgin, rec-Slurp, rec-Pate), antibodies and antibody fragments (such as single chain antibody), extracellular domain of viral membrane proteins, cell surface receptors, other disulfide-bond rich toxin peptides (such as dendrotoxin, conotoxin) and the like.
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
C07K 1/113 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs sans changement de la structure primaire
C07K 1/36 - ExtractionSéparationPurification par une combinaison de plusieurs procédés de types différents
C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
Provided are metal complexes of Formula I and metal complexes of Formula VII. Also provided are formulations comprising these metal complexes. Further provided are OLEDs and related consumer products that utilize these metal complexes.
Provided are metal complexes of Formula I and metal complexes of Formula VII. Also provided are formulations comprising these metal complexes. Further provided are OLEDs and related consumer products that utilize these metal complexes.
The disclosure provides for methods, including automated methods, of radio synthesizing certain 2'-deoxy-2'-[18F]fluoro-5-substituted-1-β-D-arabinofuranosyl-uracil and related compounds such as, for example, 2'-deoxy-2'-[18ββ-D-arabinofuranosyl-uracil ([18F]FMAU).
A system used for conducting transcranial magnetic stimulation (TMS) in a small animal is disclosed. The system may comprise: a miniaturized coil comprising C-shaped magnetic iron core having a first base and a second base, and having insulated copper wires wound around the magnetic iron core; and a stimulator that is configured to generate TMS pulses through the miniaturized coil. A method for conducting transcranial magnetic stimulation (TMS) in a small animal is also disclosed. The method may comprise: placing a miniaturized coil proximate a skull of the small animal, and generating an E-field in a brain of the small animal using the miniaturized coil.
A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants
80.
FASTING-MIMICKING DIET (FMD) AS AN INTERVENTION FOR ALZHEIMER'S DISEASE (AD)
A method of treating Alzheimer's associated pathology includes a step of identifying subject having a pathology that is associated with Alzheimer's disease. A fasting mimicking diet (FMD) is then administered to the subject for a first time period. Methods for treating amyloid plaque formation and/or elevated levels of tau protein as well as neuroinflammation are also provided.
A23L 33/20 - Diminution de la valeur nutritiveProduits diététiques avec valeur nutritive réduite
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
81.
PERSONALIZED PROFILING OF FUTURE BRAIN TRAJECTORIES AND FUTURE DISEASE EVOLUTION USING GENERATIVE ARTIFICIAL INTELLIGENCE
A system, method, and device (“system”) is provided for conducting anatomically interpretable deep learning of brain age that captures domain-specific cognitive impairment. By performing personalized profiling of future brain trajectories using generative artificial intelligence, the system facilitates early identification of neuroanatomy changes to screen individuals according to risk of neurocognitive impairments. A system may implement a generative AI model and may receive a plurality of brain data sets, extract various maps of a subject brain, and determine a salience probability map of future brain trajectory or future brain disease biomarkers based thereon. Moreover, the generative AI model may compute a training objective and the model may update based on the training objective.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
82.
SYNTHETIC TGF-BETA REDIRECTORS AND USES THEREOF IN CHIMERIC ANTIGEN RECEPTOR-MEDIATED CELL THERAPY AND OTHERS
Synthetic TGFβ receptors are provided which function as TGFβ signal redirectors to redirector immunosuppressive TGFβ signal to an immunostimulatory signal in immune cells. In various embodiments, synthetic TGFβ receptors comprise fusion proteins of an extracellular domain of TGFβ receptor and an intracellular domain of interleukin receptor, typically with a transmembrane domain derived from transmembrane domain of the interleukin receptor. Host cells are also provided, which express the synthetic TGFβ receptors. In various embodiments, T cells expressing the synthetic TGFβ receptors also contain a recombinant expression vector encoding a chimeric antigen receptor (CAR) endowed with specificity against a disease-associated antigen. In further embodiments, the CAR is driven by a thermo-responsive promoter, optionally operably linked to a NF-kB or STAT response element. Ultrasound or focused ultrasound may be used in stimulating expression of the vector in these cells.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
The disclosure provides for an engineered extracelluar vesicle and methods of using the same where the engineered extracellular vesicle comprises a first fusion protein having the formula A-B-C, wherein A is a first antibody moiety, B is a second antibody moiety, and C is a first exosomal protein transmembrane domain; and a second fusion protein comprising the formula D-E-F, wherein D is a first protein binding moiety, E is a second exosomal membrane protein transmembrane domain, and F is a second protein binding moiety; wherein both the first fusion protein and the second fusion protein are displayed on a surface of the engineered extracellular vesicle, and the first antibody moiety and the second antibody moiety separately bind to a an immune cell marker protein and a cancer cell surface-marker protein, and the first binding protein moiety and the second protein binding moiety separately bind to a second immune cell marker protein and a second cancer cell surface-marker protein.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
84.
USING GENETIC ALGORITHMS FOR SAFE SWARM TRAJECTORY OPTIMIZATION
A control system includes a target spacecraft and a swarm of chaser spacecraft. Each chaser spacecraft is controlled to follow a corresponding computed trajectory. The system also includes at least one computing device that executes a nested genetic algorithm. The nested genetic algorithm includes multiple guidance genetic algorithms and an outer genetic algorithm. Characteristically, each chaser spacecraft has an associated guidance genetic algorithm that determines a computed trajectory for the chaser spacecraft associated therewith. Advantageously, the outer genetic algorithm checks for collisions and is configured to alter one or more computed trajectories to avoid collisions.
B64G 1/24 - Appareils de guidage ou de commande, p. ex. de commande d'assiette
B64G 1/10 - Satellites artificielsSystèmes de tels satellitesVéhicules interplanétaires
B64G 1/36 - Appareils de guidage ou de commande, p. ex. de commande d'assiette par des capteurs, p. ex. par des capteurs solaires, des capteurs d'horizon
G06N 3/126 - Algorithmes évolutionnaires, p. ex. algorithmes génétiques ou programmation génétique
85.
System And Methods For Plasma-Based Remediation of SOx and NOx
B01D 53/32 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par effets électriques autres que ceux prévus au groupe
A method for treating autoimmune and/or inflammatory disease includes a step of identifying a subject exhibiting symptoms of autoimmune and/or inflammatory disease administering a fasting mimicking diet. The fasting mimicking diet provides the subject with at most 50% to 75% of the subject's normal caloric intake. A probiotic composition for gastrointestinal autoimmune and/or inflammatory disease Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof is also provided.
Described herein are functionalized peptides, compositions comprising the same, and methods useful for treatment of dental caries that have been treated with silver diamine fluoride. Treatment with functionalized peptides addresses undesirable tooth discoloration associated with silver diamine fluoride treatment and/or enhances penetration for functional integrity.
A radiofluorinated docosahexaenoic acid fatty acid and methods of making the same. Also disclosed are methods of using the radiofluorinated docosahexaenoic acid fatty acid for use in multimodal imaging, such as positron emission tomography (PET) scans.
Systems and methods are disclosed for a 3D microfluidic channel manufacturing device comprising: a main build platform and an auxiliary build platform, for printing microfluidic channels in a 3D printed product.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
B29C 64/129 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective caractérisés par la source d'énergie à cet effet, p. ex. par irradiation globale combinée avec un masque
A bipedal robot having five degree of freedom leg assemblies is disclosed. The example leg assemblies each have a hip joint; a thigh link assembly rotatably coupled to the hip joint; and a knee joint coupled to the thigh link assembly. A calf link assembly is rotatably coupled to the knee joint. An ankle joint is coupled to the calf link assembly. A set of actuators is configured to control movement of the leg assembly. At least some of the actuators are positioned near the hip joint to concentrate mass of the leg assembly proximate to the hip joint. A transmission system is configured to transmit force from at least one of the actuators to either the knee joint or the ankle joint of the leg assembly.
B62D 57/032 - Véhicules caractérisés par des moyens de propulsion ou de prise avec le sol autres que les roues ou les chenilles, seuls ou en complément aux roues ou aux chenilles avec moyens de propulsion en prise avec le sol, p. ex. par jambes mécaniques avec une base de support et des jambes soulevées alternativement ou dans un ordre déterminéVéhicules caractérisés par des moyens de propulsion ou de prise avec le sol autres que les roues ou les chenilles, seuls ou en complément aux roues ou aux chenilles avec moyens de propulsion en prise avec le sol, p. ex. par jambes mécaniques avec des pieds ou des patins soulevés alternativement ou dans un ordre déterminé
A63H 11/18 - Figurines qui exécutent un mouvement naturel de marche
91.
A MODULAR TOOL FOR TRANSSYNAPTIC LABELING BASED ANTIBODY MIMETICS
Provided herein are methods and compositions for anterograde postsynaptic tracing which preferably do not affect synaptic transmission. The methods and compositions may be used to deliver polypeptide payloads to postsynaptic neurons in a manner that is exclusively transsynaptic, monosynaptic, nontoxic, and without retrograde spread.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A modular acoustic sensor assembly and method of forming the same is disclosed comprising: a two-dimensional acoustic sensor array; an electrically conducting and acoustically attenuating interposer; an assembly connection layer; and a first routing subassembly, wherein at least one electrical routing plane of the interposer is substantially parallel to a principal electrical routing plane of the routing substrate.
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
B33Y 80/00 - Produits obtenus par fabrication additive
G01S 7/52 - Détails des systèmes correspondant aux groupes , , de systèmes selon le groupe
G01S 15/89 - Systèmes sonar, spécialement adaptés à des applications spécifiques pour la cartographie ou la représentation
93.
INTERLEAVED FLOW-SENSITIVE DEPHASING (IFSD) FOR ENHANCED BLOOD FLOW SUPPRESSION AND PRESERVED T1-WEIGHTED CONTRAST AND OVERALL SIGNAL INTENSITY IN 3D TURBO SPIN-ECHO IMAGING
Systems, computer-readable medium, methods and apparatus, and/or devices are provided interleaved flow-sensitive dephasing. The disclosed dephasing enhances flow-suppression capability that makes 3D T1-weighted turbo-spin echo (TSE) imaging useful for brain metastasis detection and intracranial vessel wall and venous sinus imaging. The disclosed mechanisms suppress residual flow artifacts mimicking pathological features, while maintaining signal quality and T-1 weighted contrast, maintaining the diagnostic performance of 3D TSE.
G01R 33/561 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.-à-d. systèmes d'acquisition rapide, p. ex. utilisant des séquences d'impulsions écho-planar
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
Novel compounds such as DHMP maintain DHM features and pharmacological activities with increased potency and efficacy, improved water solubility, enhanced bioavailability, increased permeability to the blood brain barrier (BBB), and increased stability. Because DHMP retains the therapeutic activities of DHM and has properties that improve its bioavailability, it can be used as a therapeutic agent for treating Alzheimer's disease-related diseases (ADRD) including Alzheimer's disease (AD), Vascular Dementia, Frontotemporal Dementia (FTD), Mixed Dementia as well as neurodegeneration such as Parkinson's disease. Administration of these compounds result in beneficial pathological changes including reduction of Aꞵ and Tau, improvement of neuroinflammation, reduction of cognitive/memory deficits, as well as improvement of anxiety, depression, and aggression. The disclosed DHM derivatives can also be used to treat sleep disorders, neurological disorders such as PTSD, Autism, Epilepsy/Seizures, and Alcohol Use Disorders (AUD), fetal alcohol syndrome (FAD), substance addictions, and cancers.
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Aspects of this technical solution can include obtaining, by a first device, a first data stream carrying a first two-bit number mapped to one or more phase-encoded optical signals, obtaining, by a second device, a second data stream carrying a second two-bit number mapped to the one or more phase-encoded optical signals, encoding, based on the one or more quadrature-phase-shift-keying phases, the first data stream, and the second data stream in a 4-phase-encoded modulation format, performing the average operation on the two transmitted optical signals, and multicasting the result of the average operation to the wavelength of the two transmitted optical channels by nonlinear wave mixing.
Victor Babes University of Medicine and Pharmacy Timisoara (Roumanie)
COPD Foundation, Inc. (USA)
Inventeur(s)
Bogdan, Paul
Cheng, Mingxi
Gupta, Gaurav
Lihu, Andrei
Mannino, David
Mihaicuta, Stefan
Udrescu, Mihai
Udrescu, Lucretia
Yin, Chenzhong
Abrégé
Applicant discloses herein relate to systems, methods, apparatuses, and non-transitory computer readable media for generating physiological signals datasets, analyzing physiological signals in the physiological signals datasets, extract fractional dynamics signatures specific to Chronic Obstructive Pulmonary Disease (COPD) medical records, and identifying, using a deep neural network (DNN), a COPD stage.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
97.
MULTIWAVELET-BASED OPERATOR LEARNING FOR DIFFERENTIAL EQUATIONS
The solution of a partial differential equation can be obtained by computing the inverse operator map between the input and the solution space. Described herein is a multiwavelet-based neural operator learning scheme that compresses the associated operator's kernel using fine-grained wavelets. The system embeds the inverse multiwavelet filters to learn the projection of the kernel onto fixed multiwavelet polynomial bases. The projected kernel is trained at multiple scales derived from using repeated computation of multiwavelet transform. This allows learning the complex dependencies at various scales and results in a resolution-independent scheme. These techniques exploit the fundamental properties of the operator's kernel, which enables numerically efficient representation. These techniques show significantly higher accuracy in a large range of datasets. By learning the mappings between function spaces, these techniques can be used to find the solution of a high-resolution input after learning from lower-resolution data.
Provided are compounds comprising at least one monoanionic bidentate ligand LA represented by Formula I or a tautomer thereof. Also provided are formulations comprising compounds. Further provided are OLEDs and related consumer products that utilize these compounds.
Provided are compounds comprising at least one monoanionic bidentate ligand LA represented by Formula I or a tautomer thereof. Also provided are formulations comprising compounds. Further provided are OLEDs and related consumer products that utilize these compounds.
The present disclosure provides amide M carbene emitters of Formula (I); organic light emitting device (OLED) comprising an anode, a cathode, and an organic layer, disposed between the anode and the cathode, comprising a compound of Formula (I); and consumer products comprising an OLED comprising a compound of Formula (I):
The present disclosure provides amide M carbene emitters of Formula (I); organic light emitting device (OLED) comprising an anode, a cathode, and an organic layer, disposed between the anode and the cathode, comprising a compound of Formula (I); and consumer products comprising an OLED comprising a compound of Formula (I):
Systems, methods and devices are provided for evaluating changes in the human cerebral cortex from computed tomography. These may include regional segmentation and parcellation of the human cerebral cortex. Such a method may include receiving a plurality of brain images, segmenting aspects of the imaging, and performing other processing, such as correcting a radiodensity gradient, performing linear translations, and/or other steps. The system, methods, and devices may characterize brain volumes from the aggregated brain data. In this manner, changes in the brain may be determined.
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients